D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|March 30, 2012
Conference Coverage From AACE Coming Soon
Author(s)Onclive Team
Stay tuned for live coverage from the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress.
Advertisement
Stay tuned for live coverage from the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.
The conference will feature new products and devices as well as cutting edge research.
Find out more at
Not signed up to receive OncLive emails? Make an account today to make sure you don't miss updates from the AACE meeting.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5